ERBB2 and breast cancer: Increased matrix rigidity induced by YAP/TAZ activation also led to resistance to the HER2 tyrosine-kinase inhibitor (TKI) lapatinib in HER2-amplified breast cancer cells when cultured on substrates engineered to mimic different levels of matrix rigidity [46].